Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma: a Phase II, Single-arm, Prospective Study

NCT05954897 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.

NCT NCT05954897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05954897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma: a Phase II, Single-arm, Prospective Study
Lead sponsor
Guangdong Provincial People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2023
Completion date
January 1, 2027
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma